“…Likewise, if we consider the main outcomes to immunotherapy in NSCLC, most of the CheckMate and KEYNOTE trials were done in the United States and Europe, and they did not include or included a minimal number of Hispanics. Recently, Raez et al 25 reported information from 256 Hispanic patients with NSCLC treated with immunotherapy (mainly as second-line therapy) in Argentina, Peru, and the United States (Miami). In parallel, the authors matched these data with 180 NHW controls, finding no difference in outcomes (progression-free survival [PFS] and overall survival [OS]) at 4 and 22 months.…”